drugset / Trial / NCT00418132
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Phase 1
Terminated
30 enrolled
NYU Langone Health
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc. Thalidomide is a medication that has been shown to stimulate an immune response that reduces the body's synthesis of collagen, the main component of connective tissue. This study will determine the effectiveness of thalidomide in treating adults with SSc.
Timeline
- Start
- 2000-08
- Primary completion
- —
- Completion
- 2007-10
Outcome
Outcome not reported
Stopped (Enrollment): “Study terminated early due to difficulties in subject recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 300 mg | — |